Natera Q2 revenue $261.4M (+31.9% YoY); net loss narrows; raises FY 2023 guidance

Natera, Inc.

2023-Q2 EPS reported -$2.20 revenue$503,160,000

Total revenue $261.4M, up 31.9% YoY; product revenue $258.3M (+32.7%).
Net loss $110.8M ($0.97/shr) vs loss $145.2M ($1.50/shr) YoY; operating loss $112.4M.
Tests processed 617,200 (+23.5% YoY); oncology tests 83,500 (+88.9% YoY).
Raised FY 2023 revenue guidance to $1.015B-$1.035B vs prior $995M-$1.015B.
Won litigation: $19.35M damages from ArcherDX/Invitae; CareDx damages reduced to $0.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Natera, Inc. reported the second quarter ended June 30, 2023 results: revenue $261.4 million, net income $110.8 million, EPS ($0.97) per diluted share. Guidance raised.

Period: the second quarter ended June 30, 2023
Revenue: $261.4 million
Net income: $110.8 million
EPS: ($0.97) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

in cell-free DNA testing , today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 million in the second quarter of 2022, an increase of 31.9%. Product revenues grew 32.7% over the same period. ● Processed

View on SEC.gov

Browse all earnings releases →

Natera, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-087265

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.